Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol

INTRODUCTION: Traumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed. Traditional medicine MLC901 (NeuroAiD II) with neuroprotective and neuroproliferative properties in cellular and animal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilipenko, Pavel, Ivanova, Anna Andreevna, Kotsiubinskaya, Yulia Vadimovna, Feigin, Valery, Majdan, Marek, Grigoryeva, Vera Naumovna, Khrulev, Alexey Yevgenievich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014072/
https://www.ncbi.nlm.nih.gov/pubmed/35418437
http://dx.doi.org/10.1136/bmjopen-2021-059167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014072/
https://www.ncbi.nlm.nih.gov/pubmed/35418437
http://dx.doi.org/10.1136/bmjopen-2021-059167

Ejemplares similares